AML-432 Overall Survival (OS) by Mutant Allele (R140 or R172) in Patients With Late-Stage, Mutant- Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY TrialCourtney D. DiNardo, Maroof Hasan, Alberto Risueño et al.|Clinical Lymphoma Myeloma & Leukemia|2022Cited by 0
Therapeutic potential of FLT4-targeting peptide in acute myeloid leukemiaJi Yoon Lee, Hee‐Je Kim|Research Square|2022Cited by 0